<qa>  What is the name of the study that does not prevent patients from being listed for liver transplantationParticipants will be randomly chosen to receive either diflunisal or an inactive placebo pill twice daily for 24 months. Participants will be carefully monitored through 7 follow-up visits, either at the study center or with individual primary care physicians. Participating in the study does not preclude patients from being listed for liver transplantation. 